Genmab A (GMAB) Research & Development (2018 - 2026)

Genmab A has reported Research & Development for 6 years, with the latest figure at -$440.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 22.56% year-over-year to -$440.0 million; the trailing twelve-month figure through Mar 2026 stood at -$1.5 billion (down 9.27% YoY), and the FY2025 full-year result was $1.6 billion, up 13.58% from the prior year.
• Research & Development for Q1 2026 stood at -$440.0 million, down from -$357.0 million in the prior quarter.
• The five-year high for Research & Development was -$335.0 million in Q1 2024, with the low at -$440.0 million in Q1 2026.
• Historically, Research & Development has averaged -$364.6 million across 3 years, with a median of -$359.0 million in 2025.
• Annual changes were most pronounced in 2025 — Research & Development dropped 0.83% — and 2026, when it retreated 22.56%.
• Genmab A's Research & Development stood at -$336.0 million in 2024, then dropped by 6.25% to -$357.0 million in 2025, then slipped by 23.25% to -$440.0 million in 2026.
• The last three Research & Development figures came in at -$440.0 million (Q1 2026), -$357.0 million (Q3 2025), and -$364.0 million (Q2 2025), per Business Quant data.